Test Price
2,800 AEDโ Home Collection Available
NSDHL Gene CHILD Syndrome Genetic Test (NGS) in UAE | 2800 AED | DHA Licensed
Executive Summary & Core Metrics
This ISO-certified Next-Generation Sequencing (NGS) test provides definitive molecular diagnosis of CHILD syndrome by full-gene sequencing of NSDHL with 99.9% analytical sensitivity, strictly adhering to DHA regulatory standards. The service includes VIP mobile phlebotomy with temperature-controlled cold-chain home collection, pre- and post-test genetic counselling, and encrypted report delivery. Insurance verification is available via WhatsApp. All clinical data is handled under UAE Federal Decree-Law No. 45 of 2021 on Personal Data Protection (PDPL) and Federal Law No. 2 of 2019 concerning health information technology.
Test Overview & Methodology
This test utilises next-generation sequencing to detect pathogenic variants in the NSDHL gene, confirming a clinical diagnosis of Congenital Hemidysplasia with Ichthyosiform erythroderma and Limb Defects (CHILD) syndrome โ an X-linked dominant disorder primarily affecting skin, limbs, and occasionally the central nervous system. Early molecular diagnosis guides targeted management, family genetic counselling, and prenatal/preimplantation planning.
| Features | Our NSDHL NGS Test | Alternative Sanger Sequencing |
|---|---|---|
| Method | Next-Generation Sequencing (full gene with exon-level coverage) | Sanger sequencing (targeted, variant-by-variant) |
| Analytical Sensitivity | 99.9% (detects SNVs, small indels) | ~95% for targeted regions |
| Turnaround Time | 3โ4 weeks | 4โ6 weeks per variant |
| Comprehensiveness | Whole coding region, splice sites, and deep intronic regions | Only selected exons or known mutation hotspots |
| Price | 2,800 AED | 2,200โ2,500 AED (may require sequential variants) |
Physician Insight & Safety Protocols
โGenetic testing for CHILD syndrome provides a roadmap, not a verdict. A thorough understanding of the result in conjunction with clinical findings empowers families to make informed decisions. I recommend all patients discuss their results with a clinical geneticist or dermatologist before any treatment changes.โ โ Lina Osama Zaki Quteineh, Consultant Medical Genetics, DHA Registration ID: 9294403.
Advisory: Clinical Correlation Required
Test results must always be interpreted in the context of the full clinical picture. Do not alter or discontinue any prescribed therapy solely based on genetic findings. A clinical consultation with the ordering physician is mandatory before any therapeutic decision.
Safety Exclusion Criteria & Emergency Red Flags
- Not eligible for blood draw: Patients who have undergone allogeneic bone marrow transplantation within the last 6 months, as donor DNA may confound results. Use buccal swab or skin biopsy after consultation.
- Acute illness: High fever, active infection, or severe dermatitis at collection site may postpone sample collection until stabilised.
- Emergency symptoms: If the patient develops sudden severe skin blistering, progressive limb deformity with pain, or acute neurological signs (seizures, altered consciousness), seek immediate hospital care โ do not wait for test results.
- Minors: Genetic testing of children requires explicit consent from both parents or legal guardians, in compliance with UAE Federal Decree-Law No. 4 of 2016 on Medical Liability.
Patient FAQ & Clinical Guidance
1. What is the NSDHL Gene CHILD Syndrome Genetic Test?
This advanced genetic test sequences your entire NSDHL gene using next-generation technology to identify mutations responsible for CHILD syndrome, a rare X-linked dominant disorder with skin, limb, and sometimes neurological involvement. The test detects single nucleotide variants and small insertions/deletions that may not be found by older methods. A positive result confirms diagnosis and enables cascade testing in family members. A negative result reduces need for invasive investigations and directs clinicians toward alternative diagnoses.
2. Who should consider having the NSDHL Gene CHILD Syndrome NGS Test?
Individuals with clinical features of CHILD syndrome (unilateral ichthyosiform erythroderma, ipsilateral limb defects, and/or punctuate epiphyseal calcifications) need this test for definitive molecular confirmation. It is also indicated for female carriers with a family history, mothers of affected boys, and couples planning pregnancy who seek preimplantation genetic diagnosis. Newborns with suggestive skin findings benefit from early testing to initiate multidisciplinary care. Genetic counselling is mandatory before sampling per UAE Federal Decree-Law No. 4 of 2016 on Medical Liability.
3. How accurate is this test and how are my data protected?
The NSDHL NGS achieves 99.9% analytical sensitivity and >99.5% specificity, confirmed by ISO 9001:2015 certified processes and regular proficiency testing through EMQN external quality assessment schemes. All patient data is handled under UAE Personal Data Protection Law (PDPL) using end-to-end encryption, and genetic information is never shared with employers, insurers, or third parties without explicit consent. Reports are reviewed by DHA-licensed clinical geneticists and only released to the ordering physician or through a secure patient portal.
UAE Regulatory & Data Privacy Adherence
ISO 9001:2015 Certified | Certificate: INT/EGQ/2509DA/3139 โข UAE Federal Decree-Law No. 45 of 2021 (PDPL) Compliance โข Federal Law No. 2 of 2019 Concerning the Use of Information and Communication Technology in Health Fields โข Lab License: DHA Facility License Number 1143 โข DHA Pre-approval Code for Genetic Testing: DHA-GEN-NSDHL
Clinical & Logistical Metadata
| Test Name | NSDHL Gene CHILD Syndrome Genetic Test (NGS) |
| Price (AED) | 2,800 AED |
| Turnaround Time | 3โ4 weeks |
| Sample Type / Matrix | Peripheral whole blood (EDTA tube) โ VIP Mobile Phlebotomy & Temperature-Controlled Cold-Chain Home Collection available daily from 8 AM to 11 PM |
| Methodology Used | Next-Generation Sequencing (full gene with exon-level coverage) |
| ICD-10-CM Code | Q87.2 (Congenital malformation syndromes predominantly involving limbs) |
| LOINC Code | 21621-4 (Gene mutation analysis by sequencing) |
| DHA Facility License & Laboratory Address | DHA Facility License Number: 1143 | Premises 105, Floor 1, Building 33, Dubai Healthcare City, Dubai, UAE โ DNA Labs UAE |
ุฏุนู ุซูุงุฆู ุงููุบุฉ ู ุชุงุญ
ุงูุชุญูู ู ู ุงูุชุบุทูุฉ ุงูุชุฃู ูููุฉ
Check Insurance Coverage Instantly
Stop the guesswork. Send a photo of your Insurance Card and Doctor's Prescription to our DHA-Certified Verification Team on WhatsApp.
ุชููู ุนู ุงูุชุฎู ูู. ุฃุฑุณู ุตูุฑุฉ ู ู ุจุทุงูุฉ ุงูุชุฃู ูู ููุตูุฉ ุงูุทุจูุจ ุฅูู ูุฑูู ุงูุชุญูู ุงูู ุนุชู ุฏ ู ู ููุฆุฉ ุงูุตุญุฉ ุจุฏุจู ุนุจุฑ ุงููุงุชุณุงุจ. ุงุญุตู ุนูู ุชุญุฏูุซ ุงูุญุงูุฉ ูู ุฏูุงุฆู.
Available in Arabic, English, Hindi & Urdu
ISMS 27001:2022
ISO Accredited
HIPAA
All reports reviewed by DHA-Certified physicians